LOGIN
Ankle arthrodesis: rhPDGF-BB/TCP is an effective and safe alternative to autograft
October 2013
Ankle arthrodesis: rhPDGF-BB/TCP is an effective and safe alternative to autograft
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Recombinant Human Platelet-Derived Growth Factor-BB and Beta-Tricalcium Phosphate (rhPDGF-BB/B-TCP): An Alternative to Autogenous Bone Graft
J Bone Joint Surg Am. 2013 Jul 3;95(13):1184-92. doi: 10.2106/JBJS.K.01422Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Four hundred and thirty four patients in need of either an ankle or hindfoot arthrodesis were randomized to undergo the procedure using either the recombinant human (rh) PDGF-BB/TCP or autograft as bone fusion promoters to determine the non-inferiority of rhPDGF-BB/TCP. Results indicated that rhPDGF-BB/TCP proved to be non-inferior to autograft with respect to fusion rates, clinical union, radiogr...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.